Incretin-Based Drugs Market Report 2026

The incretin-based drugs market size has grown strongly in recent years. It will grow from $27.83 billion in 2025 to $29.88 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to type 2 diabetes prevalence, insulin resistance rates, lifestyle-related metabolic disorders, endocrinology drug adoption, hospital diabetes programs.

The incretin-based drugs market size is expected to see strong growth in the next few years. It will grow to $39.25 billion in 2030 at a compound annual growth rate (CAGR) of 7.1%. The growth in the forecast period can be attributed to global obesity epidemic, weight management drug demand, long-acting incretin innovation, personalized diabetes care, preventive metabolic health focus. Major trends in the forecast period include rapid adoption of glp-1 receptor agonists, expansion of obesity management indications, increased use of oral incretin therapies, growing combination therapy approaches, improved patient adherence through weekly dosing.

The increasing prevalence of type 2 diabetes mellitus is expected to drive growth in the incretin-based drugs market in the coming years. Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to elevated blood glucose levels. Its rising prevalence is primarily due to poor diet and physical inactivity, which contribute to insulin resistance and reduce the body’s ability to regulate blood sugar. Incretin-based drugs improve type 2 diabetes management by enhancing insulin release after meals and reducing glucagon production, thereby lowering blood sugar levels. They also slow gastric emptying and suppress appetite, supporting glucose control and weight management. For example, according to the National Health Service in June 2024, approximately 549,000 more people in England were at risk of developing type 2 diabetes in 2023, bringing the total number with pre-diabetes to over 3.6 million - a nearly 20% increase from 2022. Consequently, the rising prevalence of type 2 diabetes mellitus is fueling growth in the incretin-based drugs market.

Key companies in the incretin-based drugs market are focusing on developing generic versions to provide more effective and patient-friendly treatment options for type 2 diabetes. Generic drugs contain the same active ingredients, strength, dosage form, and route of administration as brand-name drugs but are marketed under their chemical name without brand labeling. For instance, in December 2024, Hikma Pharmaceuticals PLC, a UK-based pharmaceutical company, launched the first generic version of Victoza (liraglutide) injection, 6 mg/mL, in the United States, following FDA approval. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes, providing a more affordable option amid ongoing shortages of GLP-1 medications.

In July 2024, Roche, a Switzerland-based pharmaceutical company, acquired Carmot Therapeutics for approximately $2.7 billion. This acquisition strengthens Roche’s position in the rapidly expanding obesity and metabolic disease market by integrating Carmot’s innovative injectable and oral therapies into its pharmaceuticals division. Carmot Therapeutics is a US-based clinical-stage biotechnology company specializing in obesity and diabetes, with a focus on incretin-based therapies, including GLP-1 and GIP receptor agonists.

Major companies operating in the incretin-based drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Takeda Pharmaceutical Company Limited, Amgen Inc., Novo Nordisk A/S, Viatris, Boehringer Ingelheim GmbH, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the incretin-based drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the incretin-based drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the incretin-based drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the incretin-based drugs market by increasing costs for active pharmaceutical ingredients, injectable delivery devices, and formulation excipients used in GLP-1 agonists and DPP-4 inhibitors. Injectable diabetes and obesity therapies are most affected, particularly in North America and Europe, where a significant portion of APIs and pen-delivery systems are sourced internationally. Hospital and retail pharmacies are experiencing higher acquisition costs that impact patient access. On the positive side, tariffs are accelerating domestic API manufacturing and local fill-and-finish operations for incretin-based drugs.

The incretin-based drugs market research report is one of a series of new reports that provides incretin-based drugs market statistics, including incretin-based drugs industry global market size, regional shares, competitors with a incretin-based drugs market share, detailed incretin-based drugs market segments, market trends and opportunities, and any further data you may need to thrive in the incretin-based drugs industry. This incretin-based drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Incretin-based drugs are medications used to manage type 2 diabetes by enhancing the action of incretin hormones, which stimulate insulin release after meals. These drugs help regulate blood sugar levels, reduce appetite, and support weight loss. They also lower the risk of sharp blood sugar spikes and generally do not cause severe hypoglycemia.

The main types of incretin-based drugs include glucagon-like peptide-1 receptor (GLP-1) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. GLP-1 receptor agonists imitate natural GLP-1 to boost insulin, suppress glucagon, slow gastric emptying, and lower blood sugar in type 2 diabetes and obesity. They are administered via oral or injectable routes and distributed through hospital pharmacies, retail pharmacies, and online pharmacies for applications such as type 2 diabetes, obesity, and related conditions.

The incretin-based drugs market consists of sales of dual or multi-agonists, glucagon receptor co-agonists, and fixed-dose combination drugs. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the drugs, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the drugs.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.